Global Biologics and Biosimilars Market 2025 by Company, Regions, Type and Application, Forecast to 2031
According to our (Global Info Research) latest study, the global Biologics and Biosimilars market size was valued at US$ 454100 million in 2024 and is forecast to a readjusted size of USD 797670 million by 2031 with a CAGR of 8.5% during review period.
Biologics are very specific, highly effective medicines made in living cells, and historically this was often an animal. Biologics include hormones, cytokines, growth factors, vaccines, gene and cellular therapies, fusion proteins, insulin, interferon, and monoclonal antibody (mAb) products.
A biosimilar (also known as follow-on biologic or subsequent entry biologic) is a biologic medical product that is almost an identical copy of an original product that manufactured by a different company. Biosimilar are officially approved versions of original 'innovator' products and can manufactured when the original product's patent expires. Reference to the innovator product is an integral component of the approval.
Global key biologics and biosimilars manufacturers include Johnson & Johnson, Pfizer, Roche, Amgen, AbbVie, and others. The top five manufacturers together account for approximately 50% of the market share, with the largest manufacturer being Pfizer with over 20% share. In terms of product categories, monoclonal antibodies are the largest segment with a market share of 43%, followed by vaccines with a 30% share. In terms of applications, hospitals are the top application area, with about 85% of the market share.
This report is a detailed and comprehensive analysis for global Biologics and Biosimilars market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Biologics and Biosimilars market size and forecasts, in consumption value ($ Million), 2020-2031
Global Biologics and Biosimilars market size and forecasts by region and country, in consumption value ($ Million), 2020-2031
Global Biologics and Biosimilars market size and forecasts, by Type and by Application, in consumption value ($ Million), 2020-2031
Global Biologics and Biosimilars market shares of main players, in revenue ($ Million), 2020-2025
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Biologics and Biosimilars
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Biologics and Biosimilars market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Roche, Amgen, AbbVie, Sanofi, Johnson & Johnson, Pfizer, Novo Nordisk, Eli Lilly, Novartis, Merck, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market segmentation
Biologics and Biosimilars market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Biologics and Biosimilars product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Biologics and Biosimilars, with revenue, gross margin, and global market share of Biologics and Biosimilars from 2020 to 2025.
Chapter 3, the Biologics and Biosimilars competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2020 to 2031
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2020 to 2025.and Biologics and Biosimilars market forecast, by regions, by Type and by Application, with consumption value, from 2026 to 2031.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Biologics and Biosimilars.
Chapter 13, to describe Biologics and Biosimilars research findings and conclusion.
Biologics are very specific, highly effective medicines made in living cells, and historically this was often an animal. Biologics include hormones, cytokines, growth factors, vaccines, gene and cellular therapies, fusion proteins, insulin, interferon, and monoclonal antibody (mAb) products.
A biosimilar (also known as follow-on biologic or subsequent entry biologic) is a biologic medical product that is almost an identical copy of an original product that manufactured by a different company. Biosimilar are officially approved versions of original 'innovator' products and can manufactured when the original product's patent expires. Reference to the innovator product is an integral component of the approval.
Global key biologics and biosimilars manufacturers include Johnson & Johnson, Pfizer, Roche, Amgen, AbbVie, and others. The top five manufacturers together account for approximately 50% of the market share, with the largest manufacturer being Pfizer with over 20% share. In terms of product categories, monoclonal antibodies are the largest segment with a market share of 43%, followed by vaccines with a 30% share. In terms of applications, hospitals are the top application area, with about 85% of the market share.
This report is a detailed and comprehensive analysis for global Biologics and Biosimilars market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Biologics and Biosimilars market size and forecasts, in consumption value ($ Million), 2020-2031
Global Biologics and Biosimilars market size and forecasts by region and country, in consumption value ($ Million), 2020-2031
Global Biologics and Biosimilars market size and forecasts, by Type and by Application, in consumption value ($ Million), 2020-2031
Global Biologics and Biosimilars market shares of main players, in revenue ($ Million), 2020-2025
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Biologics and Biosimilars
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Biologics and Biosimilars market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Roche, Amgen, AbbVie, Sanofi, Johnson & Johnson, Pfizer, Novo Nordisk, Eli Lilly, Novartis, Merck, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market segmentation
Biologics and Biosimilars market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
- Monoclonal Antibodies
- Interferon
- Insulin
- Vaccines
- Others
- Hospital
- Retail Pharmacy
- Other
- Roche
- Amgen
- AbbVie
- Sanofi
- Johnson & Johnson
- Pfizer
- Novo Nordisk
- Eli Lilly
- Novartis
- Merck
- Biogen
- Celltrion
- Sobi
- 3SBIO
- Changchun High Tech
- Kanghong Pharma
- Innovent Biologics
- Gan&Lee
- Tonghua Dongbao
- United Laboratory
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Biologics and Biosimilars product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Biologics and Biosimilars, with revenue, gross margin, and global market share of Biologics and Biosimilars from 2020 to 2025.
Chapter 3, the Biologics and Biosimilars competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2020 to 2031
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2020 to 2025.and Biologics and Biosimilars market forecast, by regions, by Type and by Application, with consumption value, from 2026 to 2031.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Biologics and Biosimilars.
Chapter 13, to describe Biologics and Biosimilars research findings and conclusion.
1 MARKET OVERVIEW
1.1 Product Overview and Scope
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Biologics and Biosimilars by Type
1.3.1 Overview: Global Biologics and Biosimilars Market Size by Type: 2020 Versus 2024 Versus 2031
1.3.2 Global Biologics and Biosimilars Consumption Value Market Share by Type in 2024
1.3.3 Monoclonal Antibodies
1.3.4 Interferon
1.3.5 Insulin
1.3.6 Vaccines
1.3.7 Others
1.4 Global Biologics and Biosimilars Market by Application
1.4.1 Overview: Global Biologics and Biosimilars Market Size by Application: 2020 Versus 2024 Versus 2031
1.4.2 Hospital
1.4.3 Retail Pharmacy
1.4.4 Other
1.5 Global Biologics and Biosimilars Market Size & Forecast
1.6 Global Biologics and Biosimilars Market Size and Forecast by Region
1.6.1 Global Biologics and Biosimilars Market Size by Region: 2020 VS 2024 VS 2031
1.6.2 Global Biologics and Biosimilars Market Size by Region, (2020-2031)
1.6.3 North America Biologics and Biosimilars Market Size and Prospect (2020-2031)
1.6.4 Europe Biologics and Biosimilars Market Size and Prospect (2020-2031)
1.6.5 Asia-Pacific Biologics and Biosimilars Market Size and Prospect (2020-2031)
1.6.6 South America Biologics and Biosimilars Market Size and Prospect (2020-2031)
1.6.7 Middle East & Africa Biologics and Biosimilars Market Size and Prospect (2020-2031)
2 COMPANY PROFILES
2.1 Roche
2.1.1 Roche Details
2.1.2 Roche Major Business
2.1.3 Roche Biologics and Biosimilars Product and Solutions
2.1.4 Roche Biologics and Biosimilars Revenue, Gross Margin and Market Share (2020-2025)
2.1.5 Roche Recent Developments and Future Plans
2.2 Amgen
2.2.1 Amgen Details
2.2.2 Amgen Major Business
2.2.3 Amgen Biologics and Biosimilars Product and Solutions
2.2.4 Amgen Biologics and Biosimilars Revenue, Gross Margin and Market Share (2020-2025)
2.2.5 Amgen Recent Developments and Future Plans
2.3 AbbVie
2.3.1 AbbVie Details
2.3.2 AbbVie Major Business
2.3.3 AbbVie Biologics and Biosimilars Product and Solutions
2.3.4 AbbVie Biologics and Biosimilars Revenue, Gross Margin and Market Share (2020-2025)
2.3.5 AbbVie Recent Developments and Future Plans
2.4 Sanofi
2.4.1 Sanofi Details
2.4.2 Sanofi Major Business
2.4.3 Sanofi Biologics and Biosimilars Product and Solutions
2.4.4 Sanofi Biologics and Biosimilars Revenue, Gross Margin and Market Share (2020-2025)
2.4.5 Sanofi Recent Developments and Future Plans
2.5 Johnson & Johnson
2.5.1 Johnson & Johnson Details
2.5.2 Johnson & Johnson Major Business
2.5.3 Johnson & Johnson Biologics and Biosimilars Product and Solutions
2.5.4 Johnson & Johnson Biologics and Biosimilars Revenue, Gross Margin and Market Share (2020-2025)
2.5.5 Johnson & Johnson Recent Developments and Future Plans
2.6 Pfizer
2.6.1 Pfizer Details
2.6.2 Pfizer Major Business
2.6.3 Pfizer Biologics and Biosimilars Product and Solutions
2.6.4 Pfizer Biologics and Biosimilars Revenue, Gross Margin and Market Share (2020-2025)
2.6.5 Pfizer Recent Developments and Future Plans
2.7 Novo Nordisk
2.7.1 Novo Nordisk Details
2.7.2 Novo Nordisk Major Business
2.7.3 Novo Nordisk Biologics and Biosimilars Product and Solutions
2.7.4 Novo Nordisk Biologics and Biosimilars Revenue, Gross Margin and Market Share (2020-2025)
2.7.5 Novo Nordisk Recent Developments and Future Plans
2.8 Eli Lilly
2.8.1 Eli Lilly Details
2.8.2 Eli Lilly Major Business
2.8.3 Eli Lilly Biologics and Biosimilars Product and Solutions
2.8.4 Eli Lilly Biologics and Biosimilars Revenue, Gross Margin and Market Share (2020-2025)
2.8.5 Eli Lilly Recent Developments and Future Plans
2.9 Novartis
2.9.1 Novartis Details
2.9.2 Novartis Major Business
2.9.3 Novartis Biologics and Biosimilars Product and Solutions
2.9.4 Novartis Biologics and Biosimilars Revenue, Gross Margin and Market Share (2020-2025)
2.9.5 Novartis Recent Developments and Future Plans
2.10 Merck
2.10.1 Merck Details
2.10.2 Merck Major Business
2.10.3 Merck Biologics and Biosimilars Product and Solutions
2.10.4 Merck Biologics and Biosimilars Revenue, Gross Margin and Market Share (2020-2025)
2.10.5 Merck Recent Developments and Future Plans
2.11 Biogen
2.11.1 Biogen Details
2.11.2 Biogen Major Business
2.11.3 Biogen Biologics and Biosimilars Product and Solutions
2.11.4 Biogen Biologics and Biosimilars Revenue, Gross Margin and Market Share (2020-2025)
2.11.5 Biogen Recent Developments and Future Plans
2.12 Celltrion
2.12.1 Celltrion Details
2.12.2 Celltrion Major Business
2.12.3 Celltrion Biologics and Biosimilars Product and Solutions
2.12.4 Celltrion Biologics and Biosimilars Revenue, Gross Margin and Market Share (2020-2025)
2.12.5 Celltrion Recent Developments and Future Plans
2.13 Sobi
2.13.1 Sobi Details
2.13.2 Sobi Major Business
2.13.3 Sobi Biologics and Biosimilars Product and Solutions
2.13.4 Sobi Biologics and Biosimilars Revenue, Gross Margin and Market Share (2020-2025)
2.13.5 Sobi Recent Developments and Future Plans
2.14 3SBIO
2.14.1 3SBIO Details
2.14.2 3SBIO Major Business
2.14.3 3SBIO Biologics and Biosimilars Product and Solutions
2.14.4 3SBIO Biologics and Biosimilars Revenue, Gross Margin and Market Share (2020-2025)
2.14.5 3SBIO Recent Developments and Future Plans
2.15 Changchun High Tech
2.15.1 Changchun High Tech Details
2.15.2 Changchun High Tech Major Business
2.15.3 Changchun High Tech Biologics and Biosimilars Product and Solutions
2.15.4 Changchun High Tech Biologics and Biosimilars Revenue, Gross Margin and Market Share (2020-2025)
2.15.5 Changchun High Tech Recent Developments and Future Plans
2.16 Kanghong Pharma
2.16.1 Kanghong Pharma Details
2.16.2 Kanghong Pharma Major Business
2.16.3 Kanghong Pharma Biologics and Biosimilars Product and Solutions
2.16.4 Kanghong Pharma Biologics and Biosimilars Revenue, Gross Margin and Market Share (2020-2025)
2.16.5 Kanghong Pharma Recent Developments and Future Plans
2.17 Innovent Biologics
2.17.1 Innovent Biologics Details
2.17.2 Innovent Biologics Major Business
2.17.3 Innovent Biologics Biologics and Biosimilars Product and Solutions
2.17.4 Innovent Biologics Biologics and Biosimilars Revenue, Gross Margin and Market Share (2020-2025)
2.17.5 Innovent Biologics Recent Developments and Future Plans
2.18 Gan&Lee
2.18.1 Gan&Lee Details
2.18.2 Gan&Lee Major Business
2.18.3 Gan&Lee Biologics and Biosimilars Product and Solutions
2.18.4 Gan&Lee Biologics and Biosimilars Revenue, Gross Margin and Market Share (2020-2025)
2.18.5 Gan&Lee Recent Developments and Future Plans
2.19 Tonghua Dongbao
2.19.1 Tonghua Dongbao Details
2.19.2 Tonghua Dongbao Major Business
2.19.3 Tonghua Dongbao Biologics and Biosimilars Product and Solutions
2.19.4 Tonghua Dongbao Biologics and Biosimilars Revenue, Gross Margin and Market Share (2020-2025)
2.19.5 Tonghua Dongbao Recent Developments and Future Plans
2.20 United Laboratory
2.20.1 United Laboratory Details
2.20.2 United Laboratory Major Business
2.20.3 United Laboratory Biologics and Biosimilars Product and Solutions
2.20.4 United Laboratory Biologics and Biosimilars Revenue, Gross Margin and Market Share (2020-2025)
2.20.5 United Laboratory Recent Developments and Future Plans
3 MARKET COMPETITION, BY PLAYERS
3.1 Global Biologics and Biosimilars Revenue and Share by Players (2020-2025)
3.2 Market Share Analysis (2024)
3.2.1 Market Share of Biologics and Biosimilars by Company Revenue
3.2.2 Top 3 Biologics and Biosimilars Players Market Share in 2024
3.2.3 Top 6 Biologics and Biosimilars Players Market Share in 2024
3.3 Biologics and Biosimilars Market: Overall Company Footprint Analysis
3.3.1 Biologics and Biosimilars Market: Region Footprint
3.3.2 Biologics and Biosimilars Market: Company Product Type Footprint
3.3.3 Biologics and Biosimilars Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 MARKET SIZE SEGMENT BY TYPE
4.1 Global Biologics and Biosimilars Consumption Value and Market Share by Type (2020-2025)
4.2 Global Biologics and Biosimilars Market Forecast by Type (2026-2031)
5 MARKET SIZE SEGMENT BY APPLICATION
5.1 Global Biologics and Biosimilars Consumption Value Market Share by Application (2020-2025)
5.2 Global Biologics and Biosimilars Market Forecast by Application (2026-2031)
6 NORTH AMERICA
6.1 North America Biologics and Biosimilars Consumption Value by Type (2020-2031)
6.2 North America Biologics and Biosimilars Market Size by Application (2020-2031)
6.3 North America Biologics and Biosimilars Market Size by Country
6.3.1 North America Biologics and Biosimilars Consumption Value by Country (2020-2031)
6.3.2 United States Biologics and Biosimilars Market Size and Forecast (2020-2031)
6.3.3 Canada Biologics and Biosimilars Market Size and Forecast (2020-2031)
6.3.4 Mexico Biologics and Biosimilars Market Size and Forecast (2020-2031)
7 EUROPE
7.1 Europe Biologics and Biosimilars Consumption Value by Type (2020-2031)
7.2 Europe Biologics and Biosimilars Consumption Value by Application (2020-2031)
7.3 Europe Biologics and Biosimilars Market Size by Country
7.3.1 Europe Biologics and Biosimilars Consumption Value by Country (2020-2031)
7.3.2 Germany Biologics and Biosimilars Market Size and Forecast (2020-2031)
7.3.3 France Biologics and Biosimilars Market Size and Forecast (2020-2031)
7.3.4 United Kingdom Biologics and Biosimilars Market Size and Forecast (2020-2031)
7.3.5 Russia Biologics and Biosimilars Market Size and Forecast (2020-2031)
7.3.6 Italy Biologics and Biosimilars Market Size and Forecast (2020-2031)
8 ASIA-PACIFIC
8.1 Asia-Pacific Biologics and Biosimilars Consumption Value by Type (2020-2031)
8.2 Asia-Pacific Biologics and Biosimilars Consumption Value by Application (2020-2031)
8.3 Asia-Pacific Biologics and Biosimilars Market Size by Region
8.3.1 Asia-Pacific Biologics and Biosimilars Consumption Value by Region (2020-2031)
8.3.2 China Biologics and Biosimilars Market Size and Forecast (2020-2031)
8.3.3 Japan Biologics and Biosimilars Market Size and Forecast (2020-2031)
8.3.4 South Korea Biologics and Biosimilars Market Size and Forecast (2020-2031)
8.3.5 India Biologics and Biosimilars Market Size and Forecast (2020-2031)
8.3.6 Southeast Asia Biologics and Biosimilars Market Size and Forecast (2020-2031)
8.3.7 Australia Biologics and Biosimilars Market Size and Forecast (2020-2031)
9 SOUTH AMERICA
9.1 South America Biologics and Biosimilars Consumption Value by Type (2020-2031)
9.2 South America Biologics and Biosimilars Consumption Value by Application (2020-2031)
9.3 South America Biologics and Biosimilars Market Size by Country
9.3.1 South America Biologics and Biosimilars Consumption Value by Country (2020-2031)
9.3.2 Brazil Biologics and Biosimilars Market Size and Forecast (2020-2031)
9.3.3 Argentina Biologics and Biosimilars Market Size and Forecast (2020-2031)
10 MIDDLE EAST & AFRICA
10.1 Middle East & Africa Biologics and Biosimilars Consumption Value by Type (2020-2031)
10.2 Middle East & Africa Biologics and Biosimilars Consumption Value by Application (2020-2031)
10.3 Middle East & Africa Biologics and Biosimilars Market Size by Country
10.3.1 Middle East & Africa Biologics and Biosimilars Consumption Value by Country (2020-2031)
10.3.2 Turkey Biologics and Biosimilars Market Size and Forecast (2020-2031)
10.3.3 Saudi Arabia Biologics and Biosimilars Market Size and Forecast (2020-2031)
10.3.4 UAE Biologics and Biosimilars Market Size and Forecast (2020-2031)
11 MARKET DYNAMICS
11.1 Biologics and Biosimilars Market Drivers
11.2 Biologics and Biosimilars Market Restraints
11.3 Biologics and Biosimilars Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 INDUSTRY CHAIN ANALYSIS
12.1 Biologics and Biosimilars Industry Chain
12.2 Biologics and Biosimilars Upstream Analysis
12.3 Biologics and Biosimilars Midstream Analysis
12.4 Biologics and Biosimilars Downstream Analysis
13 RESEARCH FINDINGS AND CONCLUSION
14 APPENDIX
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
1.1 Product Overview and Scope
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Biologics and Biosimilars by Type
1.3.1 Overview: Global Biologics and Biosimilars Market Size by Type: 2020 Versus 2024 Versus 2031
1.3.2 Global Biologics and Biosimilars Consumption Value Market Share by Type in 2024
1.3.3 Monoclonal Antibodies
1.3.4 Interferon
1.3.5 Insulin
1.3.6 Vaccines
1.3.7 Others
1.4 Global Biologics and Biosimilars Market by Application
1.4.1 Overview: Global Biologics and Biosimilars Market Size by Application: 2020 Versus 2024 Versus 2031
1.4.2 Hospital
1.4.3 Retail Pharmacy
1.4.4 Other
1.5 Global Biologics and Biosimilars Market Size & Forecast
1.6 Global Biologics and Biosimilars Market Size and Forecast by Region
1.6.1 Global Biologics and Biosimilars Market Size by Region: 2020 VS 2024 VS 2031
1.6.2 Global Biologics and Biosimilars Market Size by Region, (2020-2031)
1.6.3 North America Biologics and Biosimilars Market Size and Prospect (2020-2031)
1.6.4 Europe Biologics and Biosimilars Market Size and Prospect (2020-2031)
1.6.5 Asia-Pacific Biologics and Biosimilars Market Size and Prospect (2020-2031)
1.6.6 South America Biologics and Biosimilars Market Size and Prospect (2020-2031)
1.6.7 Middle East & Africa Biologics and Biosimilars Market Size and Prospect (2020-2031)
2 COMPANY PROFILES
2.1 Roche
2.1.1 Roche Details
2.1.2 Roche Major Business
2.1.3 Roche Biologics and Biosimilars Product and Solutions
2.1.4 Roche Biologics and Biosimilars Revenue, Gross Margin and Market Share (2020-2025)
2.1.5 Roche Recent Developments and Future Plans
2.2 Amgen
2.2.1 Amgen Details
2.2.2 Amgen Major Business
2.2.3 Amgen Biologics and Biosimilars Product and Solutions
2.2.4 Amgen Biologics and Biosimilars Revenue, Gross Margin and Market Share (2020-2025)
2.2.5 Amgen Recent Developments and Future Plans
2.3 AbbVie
2.3.1 AbbVie Details
2.3.2 AbbVie Major Business
2.3.3 AbbVie Biologics and Biosimilars Product and Solutions
2.3.4 AbbVie Biologics and Biosimilars Revenue, Gross Margin and Market Share (2020-2025)
2.3.5 AbbVie Recent Developments and Future Plans
2.4 Sanofi
2.4.1 Sanofi Details
2.4.2 Sanofi Major Business
2.4.3 Sanofi Biologics and Biosimilars Product and Solutions
2.4.4 Sanofi Biologics and Biosimilars Revenue, Gross Margin and Market Share (2020-2025)
2.4.5 Sanofi Recent Developments and Future Plans
2.5 Johnson & Johnson
2.5.1 Johnson & Johnson Details
2.5.2 Johnson & Johnson Major Business
2.5.3 Johnson & Johnson Biologics and Biosimilars Product and Solutions
2.5.4 Johnson & Johnson Biologics and Biosimilars Revenue, Gross Margin and Market Share (2020-2025)
2.5.5 Johnson & Johnson Recent Developments and Future Plans
2.6 Pfizer
2.6.1 Pfizer Details
2.6.2 Pfizer Major Business
2.6.3 Pfizer Biologics and Biosimilars Product and Solutions
2.6.4 Pfizer Biologics and Biosimilars Revenue, Gross Margin and Market Share (2020-2025)
2.6.5 Pfizer Recent Developments and Future Plans
2.7 Novo Nordisk
2.7.1 Novo Nordisk Details
2.7.2 Novo Nordisk Major Business
2.7.3 Novo Nordisk Biologics and Biosimilars Product and Solutions
2.7.4 Novo Nordisk Biologics and Biosimilars Revenue, Gross Margin and Market Share (2020-2025)
2.7.5 Novo Nordisk Recent Developments and Future Plans
2.8 Eli Lilly
2.8.1 Eli Lilly Details
2.8.2 Eli Lilly Major Business
2.8.3 Eli Lilly Biologics and Biosimilars Product and Solutions
2.8.4 Eli Lilly Biologics and Biosimilars Revenue, Gross Margin and Market Share (2020-2025)
2.8.5 Eli Lilly Recent Developments and Future Plans
2.9 Novartis
2.9.1 Novartis Details
2.9.2 Novartis Major Business
2.9.3 Novartis Biologics and Biosimilars Product and Solutions
2.9.4 Novartis Biologics and Biosimilars Revenue, Gross Margin and Market Share (2020-2025)
2.9.5 Novartis Recent Developments and Future Plans
2.10 Merck
2.10.1 Merck Details
2.10.2 Merck Major Business
2.10.3 Merck Biologics and Biosimilars Product and Solutions
2.10.4 Merck Biologics and Biosimilars Revenue, Gross Margin and Market Share (2020-2025)
2.10.5 Merck Recent Developments and Future Plans
2.11 Biogen
2.11.1 Biogen Details
2.11.2 Biogen Major Business
2.11.3 Biogen Biologics and Biosimilars Product and Solutions
2.11.4 Biogen Biologics and Biosimilars Revenue, Gross Margin and Market Share (2020-2025)
2.11.5 Biogen Recent Developments and Future Plans
2.12 Celltrion
2.12.1 Celltrion Details
2.12.2 Celltrion Major Business
2.12.3 Celltrion Biologics and Biosimilars Product and Solutions
2.12.4 Celltrion Biologics and Biosimilars Revenue, Gross Margin and Market Share (2020-2025)
2.12.5 Celltrion Recent Developments and Future Plans
2.13 Sobi
2.13.1 Sobi Details
2.13.2 Sobi Major Business
2.13.3 Sobi Biologics and Biosimilars Product and Solutions
2.13.4 Sobi Biologics and Biosimilars Revenue, Gross Margin and Market Share (2020-2025)
2.13.5 Sobi Recent Developments and Future Plans
2.14 3SBIO
2.14.1 3SBIO Details
2.14.2 3SBIO Major Business
2.14.3 3SBIO Biologics and Biosimilars Product and Solutions
2.14.4 3SBIO Biologics and Biosimilars Revenue, Gross Margin and Market Share (2020-2025)
2.14.5 3SBIO Recent Developments and Future Plans
2.15 Changchun High Tech
2.15.1 Changchun High Tech Details
2.15.2 Changchun High Tech Major Business
2.15.3 Changchun High Tech Biologics and Biosimilars Product and Solutions
2.15.4 Changchun High Tech Biologics and Biosimilars Revenue, Gross Margin and Market Share (2020-2025)
2.15.5 Changchun High Tech Recent Developments and Future Plans
2.16 Kanghong Pharma
2.16.1 Kanghong Pharma Details
2.16.2 Kanghong Pharma Major Business
2.16.3 Kanghong Pharma Biologics and Biosimilars Product and Solutions
2.16.4 Kanghong Pharma Biologics and Biosimilars Revenue, Gross Margin and Market Share (2020-2025)
2.16.5 Kanghong Pharma Recent Developments and Future Plans
2.17 Innovent Biologics
2.17.1 Innovent Biologics Details
2.17.2 Innovent Biologics Major Business
2.17.3 Innovent Biologics Biologics and Biosimilars Product and Solutions
2.17.4 Innovent Biologics Biologics and Biosimilars Revenue, Gross Margin and Market Share (2020-2025)
2.17.5 Innovent Biologics Recent Developments and Future Plans
2.18 Gan&Lee
2.18.1 Gan&Lee Details
2.18.2 Gan&Lee Major Business
2.18.3 Gan&Lee Biologics and Biosimilars Product and Solutions
2.18.4 Gan&Lee Biologics and Biosimilars Revenue, Gross Margin and Market Share (2020-2025)
2.18.5 Gan&Lee Recent Developments and Future Plans
2.19 Tonghua Dongbao
2.19.1 Tonghua Dongbao Details
2.19.2 Tonghua Dongbao Major Business
2.19.3 Tonghua Dongbao Biologics and Biosimilars Product and Solutions
2.19.4 Tonghua Dongbao Biologics and Biosimilars Revenue, Gross Margin and Market Share (2020-2025)
2.19.5 Tonghua Dongbao Recent Developments and Future Plans
2.20 United Laboratory
2.20.1 United Laboratory Details
2.20.2 United Laboratory Major Business
2.20.3 United Laboratory Biologics and Biosimilars Product and Solutions
2.20.4 United Laboratory Biologics and Biosimilars Revenue, Gross Margin and Market Share (2020-2025)
2.20.5 United Laboratory Recent Developments and Future Plans
3 MARKET COMPETITION, BY PLAYERS
3.1 Global Biologics and Biosimilars Revenue and Share by Players (2020-2025)
3.2 Market Share Analysis (2024)
3.2.1 Market Share of Biologics and Biosimilars by Company Revenue
3.2.2 Top 3 Biologics and Biosimilars Players Market Share in 2024
3.2.3 Top 6 Biologics and Biosimilars Players Market Share in 2024
3.3 Biologics and Biosimilars Market: Overall Company Footprint Analysis
3.3.1 Biologics and Biosimilars Market: Region Footprint
3.3.2 Biologics and Biosimilars Market: Company Product Type Footprint
3.3.3 Biologics and Biosimilars Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 MARKET SIZE SEGMENT BY TYPE
4.1 Global Biologics and Biosimilars Consumption Value and Market Share by Type (2020-2025)
4.2 Global Biologics and Biosimilars Market Forecast by Type (2026-2031)
5 MARKET SIZE SEGMENT BY APPLICATION
5.1 Global Biologics and Biosimilars Consumption Value Market Share by Application (2020-2025)
5.2 Global Biologics and Biosimilars Market Forecast by Application (2026-2031)
6 NORTH AMERICA
6.1 North America Biologics and Biosimilars Consumption Value by Type (2020-2031)
6.2 North America Biologics and Biosimilars Market Size by Application (2020-2031)
6.3 North America Biologics and Biosimilars Market Size by Country
6.3.1 North America Biologics and Biosimilars Consumption Value by Country (2020-2031)
6.3.2 United States Biologics and Biosimilars Market Size and Forecast (2020-2031)
6.3.3 Canada Biologics and Biosimilars Market Size and Forecast (2020-2031)
6.3.4 Mexico Biologics and Biosimilars Market Size and Forecast (2020-2031)
7 EUROPE
7.1 Europe Biologics and Biosimilars Consumption Value by Type (2020-2031)
7.2 Europe Biologics and Biosimilars Consumption Value by Application (2020-2031)
7.3 Europe Biologics and Biosimilars Market Size by Country
7.3.1 Europe Biologics and Biosimilars Consumption Value by Country (2020-2031)
7.3.2 Germany Biologics and Biosimilars Market Size and Forecast (2020-2031)
7.3.3 France Biologics and Biosimilars Market Size and Forecast (2020-2031)
7.3.4 United Kingdom Biologics and Biosimilars Market Size and Forecast (2020-2031)
7.3.5 Russia Biologics and Biosimilars Market Size and Forecast (2020-2031)
7.3.6 Italy Biologics and Biosimilars Market Size and Forecast (2020-2031)
8 ASIA-PACIFIC
8.1 Asia-Pacific Biologics and Biosimilars Consumption Value by Type (2020-2031)
8.2 Asia-Pacific Biologics and Biosimilars Consumption Value by Application (2020-2031)
8.3 Asia-Pacific Biologics and Biosimilars Market Size by Region
8.3.1 Asia-Pacific Biologics and Biosimilars Consumption Value by Region (2020-2031)
8.3.2 China Biologics and Biosimilars Market Size and Forecast (2020-2031)
8.3.3 Japan Biologics and Biosimilars Market Size and Forecast (2020-2031)
8.3.4 South Korea Biologics and Biosimilars Market Size and Forecast (2020-2031)
8.3.5 India Biologics and Biosimilars Market Size and Forecast (2020-2031)
8.3.6 Southeast Asia Biologics and Biosimilars Market Size and Forecast (2020-2031)
8.3.7 Australia Biologics and Biosimilars Market Size and Forecast (2020-2031)
9 SOUTH AMERICA
9.1 South America Biologics and Biosimilars Consumption Value by Type (2020-2031)
9.2 South America Biologics and Biosimilars Consumption Value by Application (2020-2031)
9.3 South America Biologics and Biosimilars Market Size by Country
9.3.1 South America Biologics and Biosimilars Consumption Value by Country (2020-2031)
9.3.2 Brazil Biologics and Biosimilars Market Size and Forecast (2020-2031)
9.3.3 Argentina Biologics and Biosimilars Market Size and Forecast (2020-2031)
10 MIDDLE EAST & AFRICA
10.1 Middle East & Africa Biologics and Biosimilars Consumption Value by Type (2020-2031)
10.2 Middle East & Africa Biologics and Biosimilars Consumption Value by Application (2020-2031)
10.3 Middle East & Africa Biologics and Biosimilars Market Size by Country
10.3.1 Middle East & Africa Biologics and Biosimilars Consumption Value by Country (2020-2031)
10.3.2 Turkey Biologics and Biosimilars Market Size and Forecast (2020-2031)
10.3.3 Saudi Arabia Biologics and Biosimilars Market Size and Forecast (2020-2031)
10.3.4 UAE Biologics and Biosimilars Market Size and Forecast (2020-2031)
11 MARKET DYNAMICS
11.1 Biologics and Biosimilars Market Drivers
11.2 Biologics and Biosimilars Market Restraints
11.3 Biologics and Biosimilars Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 INDUSTRY CHAIN ANALYSIS
12.1 Biologics and Biosimilars Industry Chain
12.2 Biologics and Biosimilars Upstream Analysis
12.3 Biologics and Biosimilars Midstream Analysis
12.4 Biologics and Biosimilars Downstream Analysis
13 RESEARCH FINDINGS AND CONCLUSION
14 APPENDIX
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
LIST OF TABLES
Table 1. Global Biologics and Biosimilars Consumption Value by Type, (USD Million), 2020 & 2024 & 2031
Table 2. Global Biologics and Biosimilars Consumption Value by Application, (USD Million), 2020 & 2024 & 2031
Table 3. Global Biologics and Biosimilars Consumption Value by Region (2020-2025) & (USD Million)
Table 4. Global Biologics and Biosimilars Consumption Value by Region (2026-2031) & (USD Million)
Table 5. Roche Company Information, Head Office, and Major Competitors
Table 6. Roche Major Business
Table 7. Roche Biologics and Biosimilars Product and Solutions
Table 8. Roche Biologics and Biosimilars Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 9. Roche Recent Developments and Future Plans
Table 10. Amgen Company Information, Head Office, and Major Competitors
Table 11. Amgen Major Business
Table 12. Amgen Biologics and Biosimilars Product and Solutions
Table 13. Amgen Biologics and Biosimilars Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 14. Amgen Recent Developments and Future Plans
Table 15. AbbVie Company Information, Head Office, and Major Competitors
Table 16. AbbVie Major Business
Table 17. AbbVie Biologics and Biosimilars Product and Solutions
Table 18. AbbVie Biologics and Biosimilars Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 19. Sanofi Company Information, Head Office, and Major Competitors
Table 20. Sanofi Major Business
Table 21. Sanofi Biologics and Biosimilars Product and Solutions
Table 22. Sanofi Biologics and Biosimilars Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 23. Sanofi Recent Developments and Future Plans
Table 24. Johnson & Johnson Company Information, Head Office, and Major Competitors
Table 25. Johnson & Johnson Major Business
Table 26. Johnson & Johnson Biologics and Biosimilars Product and Solutions
Table 27. Johnson & Johnson Biologics and Biosimilars Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 28. Johnson & Johnson Recent Developments and Future Plans
Table 29. Pfizer Company Information, Head Office, and Major Competitors
Table 30. Pfizer Major Business
Table 31. Pfizer Biologics and Biosimilars Product and Solutions
Table 32. Pfizer Biologics and Biosimilars Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 33. Pfizer Recent Developments and Future Plans
Table 34. Novo Nordisk Company Information, Head Office, and Major Competitors
Table 35. Novo Nordisk Major Business
Table 36. Novo Nordisk Biologics and Biosimilars Product and Solutions
Table 37. Novo Nordisk Biologics and Biosimilars Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 38. Novo Nordisk Recent Developments and Future Plans
Table 39. Eli Lilly Company Information, Head Office, and Major Competitors
Table 40. Eli Lilly Major Business
Table 41. Eli Lilly Biologics and Biosimilars Product and Solutions
Table 42. Eli Lilly Biologics and Biosimilars Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 43. Eli Lilly Recent Developments and Future Plans
Table 44. Novartis Company Information, Head Office, and Major Competitors
Table 45. Novartis Major Business
Table 46. Novartis Biologics and Biosimilars Product and Solutions
Table 47. Novartis Biologics and Biosimilars Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 48. Novartis Recent Developments and Future Plans
Table 49. Merck Company Information, Head Office, and Major Competitors
Table 50. Merck Major Business
Table 51. Merck Biologics and Biosimilars Product and Solutions
Table 52. Merck Biologics and Biosimilars Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 53. Merck Recent Developments and Future Plans
Table 54. Biogen Company Information, Head Office, and Major Competitors
Table 55. Biogen Major Business
Table 56. Biogen Biologics and Biosimilars Product and Solutions
Table 57. Biogen Biologics and Biosimilars Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 58. Biogen Recent Developments and Future Plans
Table 59. Celltrion Company Information, Head Office, and Major Competitors
Table 60. Celltrion Major Business
Table 61. Celltrion Biologics and Biosimilars Product and Solutions
Table 62. Celltrion Biologics and Biosimilars Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 63. Celltrion Recent Developments and Future Plans
Table 64. Sobi Company Information, Head Office, and Major Competitors
Table 65. Sobi Major Business
Table 66. Sobi Biologics and Biosimilars Product and Solutions
Table 67. Sobi Biologics and Biosimilars Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 68. Sobi Recent Developments and Future Plans
Table 69. 3SBIO Company Information, Head Office, and Major Competitors
Table 70. 3SBIO Major Business
Table 71. 3SBIO Biologics and Biosimilars Product and Solutions
Table 72. 3SBIO Biologics and Biosimilars Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 73. 3SBIO Recent Developments and Future Plans
Table 74. Changchun High Tech Company Information, Head Office, and Major Competitors
Table 75. Changchun High Tech Major Business
Table 76. Changchun High Tech Biologics and Biosimilars Product and Solutions
Table 77. Changchun High Tech Biologics and Biosimilars Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 78. Changchun High Tech Recent Developments and Future Plans
Table 79. Kanghong Pharma Company Information, Head Office, and Major Competitors
Table 80. Kanghong Pharma Major Business
Table 81. Kanghong Pharma Biologics and Biosimilars Product and Solutions
Table 82. Kanghong Pharma Biologics and Biosimilars Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 83. Kanghong Pharma Recent Developments and Future Plans
Table 84. Innovent Biologics Company Information, Head Office, and Major Competitors
Table 85. Innovent Biologics Major Business
Table 86. Innovent Biologics Biologics and Biosimilars Product and Solutions
Table 87. Innovent Biologics Biologics and Biosimilars Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 88. Innovent Biologics Recent Developments and Future Plans
Table 89. Gan&Lee Company Information, Head Office, and Major Competitors
Table 90. Gan&Lee Major Business
Table 91. Gan&Lee Biologics and Biosimilars Product and Solutions
Table 92. Gan&Lee Biologics and Biosimilars Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 93. Gan&Lee Recent Developments and Future Plans
Table 94. Tonghua Dongbao Company Information, Head Office, and Major Competitors
Table 95. Tonghua Dongbao Major Business
Table 96. Tonghua Dongbao Biologics and Biosimilars Product and Solutions
Table 97. Tonghua Dongbao Biologics and Biosimilars Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 98. Tonghua Dongbao Recent Developments and Future Plans
Table 99. United Laboratory Company Information, Head Office, and Major Competitors
Table 100. United Laboratory Major Business
Table 101. United Laboratory Biologics and Biosimilars Product and Solutions
Table 102. United Laboratory Biologics and Biosimilars Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 103. United Laboratory Recent Developments and Future Plans
Table 104. Global Biologics and Biosimilars Revenue (USD Million) by Players (2020-2025)
Table 105. Global Biologics and Biosimilars Revenue Share by Players (2020-2025)
Table 106. Breakdown of Biologics and Biosimilars by Company Type (Tier 1, Tier 2, and Tier 3)
Table 107. Market Position of Players in Biologics and Biosimilars, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2024
Table 108. Head Office of Key Biologics and Biosimilars Players
Table 109. Biologics and Biosimilars Market: Company Product Type Footprint
Table 110. Biologics and Biosimilars Market: Company Product Application Footprint
Table 111. Biologics and Biosimilars New Market Entrants and Barriers to Market Entry
Table 112. Biologics and Biosimilars Mergers, Acquisition, Agreements, and Collaborations
Table 113. Global Biologics and Biosimilars Consumption Value (USD Million) by Type (2020-2025)
Table 114. Global Biologics and Biosimilars Consumption Value Share by Type (2020-2025)
Table 115. Global Biologics and Biosimilars Consumption Value Forecast by Type (2026-2031)
Table 116. Global Biologics and Biosimilars Consumption Value by Application (2020-2025)
Table 117. Global Biologics and Biosimilars Consumption Value Forecast by Application (2026-2031)
Table 118. North America Biologics and Biosimilars Consumption Value by Type (2020-2025) & (USD Million)
Table 119. North America Biologics and Biosimilars Consumption Value by Type (2026-2031) & (USD Million)
Table 120. North America Biologics and Biosimilars Consumption Value by Application (2020-2025) & (USD Million)
Table 121. North America Biologics and Biosimilars Consumption Value by Application (2026-2031) & (USD Million)
Table 122. North America Biologics and Biosimilars Consumption Value by Country (2020-2025) & (USD Million)
Table 123. North America Biologics and Biosimilars Consumption Value by Country (2026-2031) & (USD Million)
Table 124. Europe Biologics and Biosimilars Consumption Value by Type (2020-2025) & (USD Million)
Table 125. Europe Biologics and Biosimilars Consumption Value by Type (2026-2031) & (USD Million)
Table 126. Europe Biologics and Biosimilars Consumption Value by Application (2020-2025) & (USD Million)
Table 127. Europe Biologics and Biosimilars Consumption Value by Application (2026-2031) & (USD Million)
Table 128. Europe Biologics and Biosimilars Consumption Value by Country (2020-2025) & (USD Million)
Table 129. Europe Biologics and Biosimilars Consumption Value by Country (2026-2031) & (USD Million)
Table 130. Asia-Pacific Biologics and Biosimilars Consumption Value by Type (2020-2025) & (USD Million)
Table 131. Asia-Pacific Biologics and Biosimilars Consumption Value by Type (2026-2031) & (USD Million)
Table 132. Asia-Pacific Biologics and Biosimilars Consumption Value by Application (2020-2025) & (USD Million)
Table 133. Asia-Pacific Biologics and Biosimilars Consumption Value by Application (2026-2031) & (USD Million)
Table 134. Asia-Pacific Biologics and Biosimilars Consumption Value by Region (2020-2025) & (USD Million)
Table 135. Asia-Pacific Biologics and Biosimilars Consumption Value by Region (2026-2031) & (USD Million)
Table 136. South America Biologics and Biosimilars Consumption Value by Type (2020-2025) & (USD Million)
Table 137. South America Biologics and Biosimilars Consumption Value by Type (2026-2031) & (USD Million)
Table 138. South America Biologics and Biosimilars Consumption Value by Application (2020-2025) & (USD Million)
Table 139. South America Biologics and Biosimilars Consumption Value by Application (2026-2031) & (USD Million)
Table 140. South America Biologics and Biosimilars Consumption Value by Country (2020-2025) & (USD Million)
Table 141. South America Biologics and Biosimilars Consumption Value by Country (2026-2031) & (USD Million)
Table 142. Middle East & Africa Biologics and Biosimilars Consumption Value by Type (2020-2025) & (USD Million)
Table 143. Middle East & Africa Biologics and Biosimilars Consumption Value by Type (2026-2031) & (USD Million)
Table 144. Middle East & Africa Biologics and Biosimilars Consumption Value by Application (2020-2025) & (USD Million)
Table 145. Middle East & Africa Biologics and Biosimilars Consumption Value by Application (2026-2031) & (USD Million)
Table 146. Middle East & Africa Biologics and Biosimilars Consumption Value by Country (2020-2025) & (USD Million)
Table 147. Middle East & Africa Biologics and Biosimilars Consumption Value by Country (2026-2031) & (USD Million)
Table 148. Global Key Players of Biologics and Biosimilars Upstream (Raw Materials)
Table 149. Global Biologics and Biosimilars Typical Customers
Table 1. Global Biologics and Biosimilars Consumption Value by Type, (USD Million), 2020 & 2024 & 2031
Table 2. Global Biologics and Biosimilars Consumption Value by Application, (USD Million), 2020 & 2024 & 2031
Table 3. Global Biologics and Biosimilars Consumption Value by Region (2020-2025) & (USD Million)
Table 4. Global Biologics and Biosimilars Consumption Value by Region (2026-2031) & (USD Million)
Table 5. Roche Company Information, Head Office, and Major Competitors
Table 6. Roche Major Business
Table 7. Roche Biologics and Biosimilars Product and Solutions
Table 8. Roche Biologics and Biosimilars Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 9. Roche Recent Developments and Future Plans
Table 10. Amgen Company Information, Head Office, and Major Competitors
Table 11. Amgen Major Business
Table 12. Amgen Biologics and Biosimilars Product and Solutions
Table 13. Amgen Biologics and Biosimilars Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 14. Amgen Recent Developments and Future Plans
Table 15. AbbVie Company Information, Head Office, and Major Competitors
Table 16. AbbVie Major Business
Table 17. AbbVie Biologics and Biosimilars Product and Solutions
Table 18. AbbVie Biologics and Biosimilars Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 19. Sanofi Company Information, Head Office, and Major Competitors
Table 20. Sanofi Major Business
Table 21. Sanofi Biologics and Biosimilars Product and Solutions
Table 22. Sanofi Biologics and Biosimilars Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 23. Sanofi Recent Developments and Future Plans
Table 24. Johnson & Johnson Company Information, Head Office, and Major Competitors
Table 25. Johnson & Johnson Major Business
Table 26. Johnson & Johnson Biologics and Biosimilars Product and Solutions
Table 27. Johnson & Johnson Biologics and Biosimilars Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 28. Johnson & Johnson Recent Developments and Future Plans
Table 29. Pfizer Company Information, Head Office, and Major Competitors
Table 30. Pfizer Major Business
Table 31. Pfizer Biologics and Biosimilars Product and Solutions
Table 32. Pfizer Biologics and Biosimilars Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 33. Pfizer Recent Developments and Future Plans
Table 34. Novo Nordisk Company Information, Head Office, and Major Competitors
Table 35. Novo Nordisk Major Business
Table 36. Novo Nordisk Biologics and Biosimilars Product and Solutions
Table 37. Novo Nordisk Biologics and Biosimilars Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 38. Novo Nordisk Recent Developments and Future Plans
Table 39. Eli Lilly Company Information, Head Office, and Major Competitors
Table 40. Eli Lilly Major Business
Table 41. Eli Lilly Biologics and Biosimilars Product and Solutions
Table 42. Eli Lilly Biologics and Biosimilars Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 43. Eli Lilly Recent Developments and Future Plans
Table 44. Novartis Company Information, Head Office, and Major Competitors
Table 45. Novartis Major Business
Table 46. Novartis Biologics and Biosimilars Product and Solutions
Table 47. Novartis Biologics and Biosimilars Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 48. Novartis Recent Developments and Future Plans
Table 49. Merck Company Information, Head Office, and Major Competitors
Table 50. Merck Major Business
Table 51. Merck Biologics and Biosimilars Product and Solutions
Table 52. Merck Biologics and Biosimilars Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 53. Merck Recent Developments and Future Plans
Table 54. Biogen Company Information, Head Office, and Major Competitors
Table 55. Biogen Major Business
Table 56. Biogen Biologics and Biosimilars Product and Solutions
Table 57. Biogen Biologics and Biosimilars Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 58. Biogen Recent Developments and Future Plans
Table 59. Celltrion Company Information, Head Office, and Major Competitors
Table 60. Celltrion Major Business
Table 61. Celltrion Biologics and Biosimilars Product and Solutions
Table 62. Celltrion Biologics and Biosimilars Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 63. Celltrion Recent Developments and Future Plans
Table 64. Sobi Company Information, Head Office, and Major Competitors
Table 65. Sobi Major Business
Table 66. Sobi Biologics and Biosimilars Product and Solutions
Table 67. Sobi Biologics and Biosimilars Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 68. Sobi Recent Developments and Future Plans
Table 69. 3SBIO Company Information, Head Office, and Major Competitors
Table 70. 3SBIO Major Business
Table 71. 3SBIO Biologics and Biosimilars Product and Solutions
Table 72. 3SBIO Biologics and Biosimilars Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 73. 3SBIO Recent Developments and Future Plans
Table 74. Changchun High Tech Company Information, Head Office, and Major Competitors
Table 75. Changchun High Tech Major Business
Table 76. Changchun High Tech Biologics and Biosimilars Product and Solutions
Table 77. Changchun High Tech Biologics and Biosimilars Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 78. Changchun High Tech Recent Developments and Future Plans
Table 79. Kanghong Pharma Company Information, Head Office, and Major Competitors
Table 80. Kanghong Pharma Major Business
Table 81. Kanghong Pharma Biologics and Biosimilars Product and Solutions
Table 82. Kanghong Pharma Biologics and Biosimilars Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 83. Kanghong Pharma Recent Developments and Future Plans
Table 84. Innovent Biologics Company Information, Head Office, and Major Competitors
Table 85. Innovent Biologics Major Business
Table 86. Innovent Biologics Biologics and Biosimilars Product and Solutions
Table 87. Innovent Biologics Biologics and Biosimilars Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 88. Innovent Biologics Recent Developments and Future Plans
Table 89. Gan&Lee Company Information, Head Office, and Major Competitors
Table 90. Gan&Lee Major Business
Table 91. Gan&Lee Biologics and Biosimilars Product and Solutions
Table 92. Gan&Lee Biologics and Biosimilars Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 93. Gan&Lee Recent Developments and Future Plans
Table 94. Tonghua Dongbao Company Information, Head Office, and Major Competitors
Table 95. Tonghua Dongbao Major Business
Table 96. Tonghua Dongbao Biologics and Biosimilars Product and Solutions
Table 97. Tonghua Dongbao Biologics and Biosimilars Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 98. Tonghua Dongbao Recent Developments and Future Plans
Table 99. United Laboratory Company Information, Head Office, and Major Competitors
Table 100. United Laboratory Major Business
Table 101. United Laboratory Biologics and Biosimilars Product and Solutions
Table 102. United Laboratory Biologics and Biosimilars Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 103. United Laboratory Recent Developments and Future Plans
Table 104. Global Biologics and Biosimilars Revenue (USD Million) by Players (2020-2025)
Table 105. Global Biologics and Biosimilars Revenue Share by Players (2020-2025)
Table 106. Breakdown of Biologics and Biosimilars by Company Type (Tier 1, Tier 2, and Tier 3)
Table 107. Market Position of Players in Biologics and Biosimilars, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2024
Table 108. Head Office of Key Biologics and Biosimilars Players
Table 109. Biologics and Biosimilars Market: Company Product Type Footprint
Table 110. Biologics and Biosimilars Market: Company Product Application Footprint
Table 111. Biologics and Biosimilars New Market Entrants and Barriers to Market Entry
Table 112. Biologics and Biosimilars Mergers, Acquisition, Agreements, and Collaborations
Table 113. Global Biologics and Biosimilars Consumption Value (USD Million) by Type (2020-2025)
Table 114. Global Biologics and Biosimilars Consumption Value Share by Type (2020-2025)
Table 115. Global Biologics and Biosimilars Consumption Value Forecast by Type (2026-2031)
Table 116. Global Biologics and Biosimilars Consumption Value by Application (2020-2025)
Table 117. Global Biologics and Biosimilars Consumption Value Forecast by Application (2026-2031)
Table 118. North America Biologics and Biosimilars Consumption Value by Type (2020-2025) & (USD Million)
Table 119. North America Biologics and Biosimilars Consumption Value by Type (2026-2031) & (USD Million)
Table 120. North America Biologics and Biosimilars Consumption Value by Application (2020-2025) & (USD Million)
Table 121. North America Biologics and Biosimilars Consumption Value by Application (2026-2031) & (USD Million)
Table 122. North America Biologics and Biosimilars Consumption Value by Country (2020-2025) & (USD Million)
Table 123. North America Biologics and Biosimilars Consumption Value by Country (2026-2031) & (USD Million)
Table 124. Europe Biologics and Biosimilars Consumption Value by Type (2020-2025) & (USD Million)
Table 125. Europe Biologics and Biosimilars Consumption Value by Type (2026-2031) & (USD Million)
Table 126. Europe Biologics and Biosimilars Consumption Value by Application (2020-2025) & (USD Million)
Table 127. Europe Biologics and Biosimilars Consumption Value by Application (2026-2031) & (USD Million)
Table 128. Europe Biologics and Biosimilars Consumption Value by Country (2020-2025) & (USD Million)
Table 129. Europe Biologics and Biosimilars Consumption Value by Country (2026-2031) & (USD Million)
Table 130. Asia-Pacific Biologics and Biosimilars Consumption Value by Type (2020-2025) & (USD Million)
Table 131. Asia-Pacific Biologics and Biosimilars Consumption Value by Type (2026-2031) & (USD Million)
Table 132. Asia-Pacific Biologics and Biosimilars Consumption Value by Application (2020-2025) & (USD Million)
Table 133. Asia-Pacific Biologics and Biosimilars Consumption Value by Application (2026-2031) & (USD Million)
Table 134. Asia-Pacific Biologics and Biosimilars Consumption Value by Region (2020-2025) & (USD Million)
Table 135. Asia-Pacific Biologics and Biosimilars Consumption Value by Region (2026-2031) & (USD Million)
Table 136. South America Biologics and Biosimilars Consumption Value by Type (2020-2025) & (USD Million)
Table 137. South America Biologics and Biosimilars Consumption Value by Type (2026-2031) & (USD Million)
Table 138. South America Biologics and Biosimilars Consumption Value by Application (2020-2025) & (USD Million)
Table 139. South America Biologics and Biosimilars Consumption Value by Application (2026-2031) & (USD Million)
Table 140. South America Biologics and Biosimilars Consumption Value by Country (2020-2025) & (USD Million)
Table 141. South America Biologics and Biosimilars Consumption Value by Country (2026-2031) & (USD Million)
Table 142. Middle East & Africa Biologics and Biosimilars Consumption Value by Type (2020-2025) & (USD Million)
Table 143. Middle East & Africa Biologics and Biosimilars Consumption Value by Type (2026-2031) & (USD Million)
Table 144. Middle East & Africa Biologics and Biosimilars Consumption Value by Application (2020-2025) & (USD Million)
Table 145. Middle East & Africa Biologics and Biosimilars Consumption Value by Application (2026-2031) & (USD Million)
Table 146. Middle East & Africa Biologics and Biosimilars Consumption Value by Country (2020-2025) & (USD Million)
Table 147. Middle East & Africa Biologics and Biosimilars Consumption Value by Country (2026-2031) & (USD Million)
Table 148. Global Key Players of Biologics and Biosimilars Upstream (Raw Materials)
Table 149. Global Biologics and Biosimilars Typical Customers
LIST OF FIGURES
Figure 1. Biologics and Biosimilars Picture
Figure 2. Global Biologics and Biosimilars Consumption Value by Type, (USD Million), 2020 & 2024 & 2031
Figure 3. Global Biologics and Biosimilars Consumption Value Market Share by Type in 2024
Figure 4. Monoclonal Antibodies
Figure 5. Interferon
Figure 6. Insulin
Figure 7. Vaccines
Figure 8. Others
Figure 9. Global Biologics and Biosimilars Consumption Value by Application, (USD Million), 2020 & 2024 & 2031
Figure 10. Biologics and Biosimilars Consumption Value Market Share by Application in 2024
Figure 11. Hospital Picture
Figure 12. Retail Pharmacy Picture
Figure 13. Other Picture
Figure 14. Global Biologics and Biosimilars Consumption Value, (USD Million): 2020 & 2024 & 2031
Figure 15. Global Biologics and Biosimilars Consumption Value and Forecast (2020-2031) & (USD Million)
Figure 16. Global Market Biologics and Biosimilars Consumption Value (USD Million) Comparison by Region (2020 VS 2024 VS 2031)
Figure 17. Global Biologics and Biosimilars Consumption Value Market Share by Region (2020-2031)
Figure 18. Global Biologics and Biosimilars Consumption Value Market Share by Region in 2024
Figure 19. North America Biologics and Biosimilars Consumption Value (2020-2031) & (USD Million)
Figure 20. Europe Biologics and Biosimilars Consumption Value (2020-2031) & (USD Million)
Figure 21. Asia-Pacific Biologics and Biosimilars Consumption Value (2020-2031) & (USD Million)
Figure 22. South America Biologics and Biosimilars Consumption Value (2020-2031) & (USD Million)
Figure 23. Middle East & Africa Biologics and Biosimilars Consumption Value (2020-2031) & (USD Million)
Figure 24. Company Three Recent Developments and Future Plans
Figure 25. Global Biologics and Biosimilars Revenue Share by Players in 2024
Figure 26. Biologics and Biosimilars Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2024
Figure 27. Market Share of Biologics and Biosimilars by Player Revenue in 2024
Figure 28. Top 3 Biologics and Biosimilars Players Market Share in 2024
Figure 29. Top 6 Biologics and Biosimilars Players Market Share in 2024
Figure 30. Global Biologics and Biosimilars Consumption Value Share by Type (2020-2025)
Figure 31. Global Biologics and Biosimilars Market Share Forecast by Type (2026-2031)
Figure 32. Global Biologics and Biosimilars Consumption Value Share by Application (2020-2025)
Figure 33. Global Biologics and Biosimilars Market Share Forecast by Application (2026-2031)
Figure 34. North America Biologics and Biosimilars Consumption Value Market Share by Type (2020-2031)
Figure 35. North America Biologics and Biosimilars Consumption Value Market Share by Application (2020-2031)
Figure 36. North America Biologics and Biosimilars Consumption Value Market Share by Country (2020-2031)
Figure 37. United States Biologics and Biosimilars Consumption Value (2020-2031) & (USD Million)
Figure 38. Canada Biologics and Biosimilars Consumption Value (2020-2031) & (USD Million)
Figure 39. Mexico Biologics and Biosimilars Consumption Value (2020-2031) & (USD Million)
Figure 40. Europe Biologics and Biosimilars Consumption Value Market Share by Type (2020-2031)
Figure 41. Europe Biologics and Biosimilars Consumption Value Market Share by Application (2020-2031)
Figure 42. Europe Biologics and Biosimilars Consumption Value Market Share by Country (2020-2031)
Figure 43. Germany Biologics and Biosimilars Consumption Value (2020-2031) & (USD Million)
Figure 44. France Biologics and Biosimilars Consumption Value (2020-2031) & (USD Million)
Figure 45. United Kingdom Biologics and Biosimilars Consumption Value (2020-2031) & (USD Million)
Figure 46. Russia Biologics and Biosimilars Consumption Value (2020-2031) & (USD Million)
Figure 47. Italy Biologics and Biosimilars Consumption Value (2020-2031) & (USD Million)
Figure 48. Asia-Pacific Biologics and Biosimilars Consumption Value Market Share by Type (2020-2031)
Figure 49. Asia-Pacific Biologics and Biosimilars Consumption Value Market Share by Application (2020-2031)
Figure 50. Asia-Pacific Biologics and Biosimilars Consumption Value Market Share by Region (2020-2031)
Figure 51. China Biologics and Biosimilars Consumption Value (2020-2031) & (USD Million)
Figure 52. Japan Biologics and Biosimilars Consumption Value (2020-2031) & (USD Million)
Figure 53. South Korea Biologics and Biosimilars Consumption Value (2020-2031) & (USD Million)
Figure 54. India Biologics and Biosimilars Consumption Value (2020-2031) & (USD Million)
Figure 55. Southeast Asia Biologics and Biosimilars Consumption Value (2020-2031) & (USD Million)
Figure 56. Australia Biologics and Biosimilars Consumption Value (2020-2031) & (USD Million)
Figure 57. South America Biologics and Biosimilars Consumption Value Market Share by Type (2020-2031)
Figure 58. South America Biologics and Biosimilars Consumption Value Market Share by Application (2020-2031)
Figure 59. South America Biologics and Biosimilars Consumption Value Market Share by Country (2020-2031)
Figure 60. Brazil Biologics and Biosimilars Consumption Value (2020-2031) & (USD Million)
Figure 61. Argentina Biologics and Biosimilars Consumption Value (2020-2031) & (USD Million)
Figure 62. Middle East & Africa Biologics and Biosimilars Consumption Value Market Share by Type (2020-2031)
Figure 63. Middle East & Africa Biologics and Biosimilars Consumption Value Market Share by Application (2020-2031)
Figure 64. Middle East & Africa Biologics and Biosimilars Consumption Value Market Share by Country (2020-2031)
Figure 65. Turkey Biologics and Biosimilars Consumption Value (2020-2031) & (USD Million)
Figure 66. Saudi Arabia Biologics and Biosimilars Consumption Value (2020-2031) & (USD Million)
Figure 67. UAE Biologics and Biosimilars Consumption Value (2020-2031) & (USD Million)
Figure 68. Biologics and Biosimilars Market Drivers
Figure 69. Biologics and Biosimilars Market Restraints
Figure 70. Biologics and Biosimilars Market Trends
Figure 71. Porters Five Forces Analysis
Figure 72. Biologics and Biosimilars Industrial Chain
Figure 73. Methodology
Figure 74. Research Process and Data Source
Figure 1. Biologics and Biosimilars Picture
Figure 2. Global Biologics and Biosimilars Consumption Value by Type, (USD Million), 2020 & 2024 & 2031
Figure 3. Global Biologics and Biosimilars Consumption Value Market Share by Type in 2024
Figure 4. Monoclonal Antibodies
Figure 5. Interferon
Figure 6. Insulin
Figure 7. Vaccines
Figure 8. Others
Figure 9. Global Biologics and Biosimilars Consumption Value by Application, (USD Million), 2020 & 2024 & 2031
Figure 10. Biologics and Biosimilars Consumption Value Market Share by Application in 2024
Figure 11. Hospital Picture
Figure 12. Retail Pharmacy Picture
Figure 13. Other Picture
Figure 14. Global Biologics and Biosimilars Consumption Value, (USD Million): 2020 & 2024 & 2031
Figure 15. Global Biologics and Biosimilars Consumption Value and Forecast (2020-2031) & (USD Million)
Figure 16. Global Market Biologics and Biosimilars Consumption Value (USD Million) Comparison by Region (2020 VS 2024 VS 2031)
Figure 17. Global Biologics and Biosimilars Consumption Value Market Share by Region (2020-2031)
Figure 18. Global Biologics and Biosimilars Consumption Value Market Share by Region in 2024
Figure 19. North America Biologics and Biosimilars Consumption Value (2020-2031) & (USD Million)
Figure 20. Europe Biologics and Biosimilars Consumption Value (2020-2031) & (USD Million)
Figure 21. Asia-Pacific Biologics and Biosimilars Consumption Value (2020-2031) & (USD Million)
Figure 22. South America Biologics and Biosimilars Consumption Value (2020-2031) & (USD Million)
Figure 23. Middle East & Africa Biologics and Biosimilars Consumption Value (2020-2031) & (USD Million)
Figure 24. Company Three Recent Developments and Future Plans
Figure 25. Global Biologics and Biosimilars Revenue Share by Players in 2024
Figure 26. Biologics and Biosimilars Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2024
Figure 27. Market Share of Biologics and Biosimilars by Player Revenue in 2024
Figure 28. Top 3 Biologics and Biosimilars Players Market Share in 2024
Figure 29. Top 6 Biologics and Biosimilars Players Market Share in 2024
Figure 30. Global Biologics and Biosimilars Consumption Value Share by Type (2020-2025)
Figure 31. Global Biologics and Biosimilars Market Share Forecast by Type (2026-2031)
Figure 32. Global Biologics and Biosimilars Consumption Value Share by Application (2020-2025)
Figure 33. Global Biologics and Biosimilars Market Share Forecast by Application (2026-2031)
Figure 34. North America Biologics and Biosimilars Consumption Value Market Share by Type (2020-2031)
Figure 35. North America Biologics and Biosimilars Consumption Value Market Share by Application (2020-2031)
Figure 36. North America Biologics and Biosimilars Consumption Value Market Share by Country (2020-2031)
Figure 37. United States Biologics and Biosimilars Consumption Value (2020-2031) & (USD Million)
Figure 38. Canada Biologics and Biosimilars Consumption Value (2020-2031) & (USD Million)
Figure 39. Mexico Biologics and Biosimilars Consumption Value (2020-2031) & (USD Million)
Figure 40. Europe Biologics and Biosimilars Consumption Value Market Share by Type (2020-2031)
Figure 41. Europe Biologics and Biosimilars Consumption Value Market Share by Application (2020-2031)
Figure 42. Europe Biologics and Biosimilars Consumption Value Market Share by Country (2020-2031)
Figure 43. Germany Biologics and Biosimilars Consumption Value (2020-2031) & (USD Million)
Figure 44. France Biologics and Biosimilars Consumption Value (2020-2031) & (USD Million)
Figure 45. United Kingdom Biologics and Biosimilars Consumption Value (2020-2031) & (USD Million)
Figure 46. Russia Biologics and Biosimilars Consumption Value (2020-2031) & (USD Million)
Figure 47. Italy Biologics and Biosimilars Consumption Value (2020-2031) & (USD Million)
Figure 48. Asia-Pacific Biologics and Biosimilars Consumption Value Market Share by Type (2020-2031)
Figure 49. Asia-Pacific Biologics and Biosimilars Consumption Value Market Share by Application (2020-2031)
Figure 50. Asia-Pacific Biologics and Biosimilars Consumption Value Market Share by Region (2020-2031)
Figure 51. China Biologics and Biosimilars Consumption Value (2020-2031) & (USD Million)
Figure 52. Japan Biologics and Biosimilars Consumption Value (2020-2031) & (USD Million)
Figure 53. South Korea Biologics and Biosimilars Consumption Value (2020-2031) & (USD Million)
Figure 54. India Biologics and Biosimilars Consumption Value (2020-2031) & (USD Million)
Figure 55. Southeast Asia Biologics and Biosimilars Consumption Value (2020-2031) & (USD Million)
Figure 56. Australia Biologics and Biosimilars Consumption Value (2020-2031) & (USD Million)
Figure 57. South America Biologics and Biosimilars Consumption Value Market Share by Type (2020-2031)
Figure 58. South America Biologics and Biosimilars Consumption Value Market Share by Application (2020-2031)
Figure 59. South America Biologics and Biosimilars Consumption Value Market Share by Country (2020-2031)
Figure 60. Brazil Biologics and Biosimilars Consumption Value (2020-2031) & (USD Million)
Figure 61. Argentina Biologics and Biosimilars Consumption Value (2020-2031) & (USD Million)
Figure 62. Middle East & Africa Biologics and Biosimilars Consumption Value Market Share by Type (2020-2031)
Figure 63. Middle East & Africa Biologics and Biosimilars Consumption Value Market Share by Application (2020-2031)
Figure 64. Middle East & Africa Biologics and Biosimilars Consumption Value Market Share by Country (2020-2031)
Figure 65. Turkey Biologics and Biosimilars Consumption Value (2020-2031) & (USD Million)
Figure 66. Saudi Arabia Biologics and Biosimilars Consumption Value (2020-2031) & (USD Million)
Figure 67. UAE Biologics and Biosimilars Consumption Value (2020-2031) & (USD Million)
Figure 68. Biologics and Biosimilars Market Drivers
Figure 69. Biologics and Biosimilars Market Restraints
Figure 70. Biologics and Biosimilars Market Trends
Figure 71. Porters Five Forces Analysis
Figure 72. Biologics and Biosimilars Industrial Chain
Figure 73. Methodology
Figure 74. Research Process and Data Source
